Real-world treatment patterns and visual outcomes of faricimab in patients with neovascular age-related macular degeneration in the UK at 12 months: the FARWIDE-nAMD study

Talks, James, de Salvo, Gabriella, Patel, Praveen J., de Silva, Samantha R., Gale, Richard P., McKibbin, Martin, Varma, Deepali, Pearce, Ian, Peto, Tunde, Reynolds, Rhianon, Bailey, Clare, Downey, Louise, Kiire, Christine A., Sivaprasad, Sobha, Downey, Amanda K., James, Natalee, Chi, Gloria C., Dodds, Melanie and Dayal, Parul 2026. Real-world treatment patterns and visual outcomes of faricimab in patients with neovascular age-related macular degeneration in the UK at 12 months: the FARWIDE-nAMD study. Eye 10.1038/s41433-025-04213-2

PDF - Published Version Available under License Creative Commons Attribution. Download (1MB)

Abstract

Background The Faricimab Real-World Evidence (FARWIDE) studies are evaluating real-world outcomes of eyes with neovascular age-related macular degeneration (nAMD) or diabetic macular oedema (DMO) treated with faricimab in the UK. Here, we present results from FARWIDE–nAMD for eyes with 12 months of follow-up after faricimab initiation. Methods nAMD patient-eyes that received ≥1 faricimab injection after May 2022 at one of 35 participating UK National Health Service retinal clinics with ≥12 months of follow-up after faricimab initiation as of July 2024 were included. Treatment-naïve (TN) eyes had no prior anti-VEGF treatment. Previously treated (PT) eyes switched from an anti-VEGF to faricimab. Baseline characteristics, VA, and injection frequency were assessed. Intraocular inflammation (IOI) and presumed infectious endophthalmitis (PIE) rates were pooled for nAMD and DMO eyes with any follow-up duration on faricimab. Analyses are descriptive. Results 5854 nAMD patients (6991 eyes; 26.5% TN, 73.5% PT) were included. 83.3% of PT eyes switched from aflibercept 2.0 mg. TN eyes received a mean (SD) of 4.7 (0.7) faricimab injections in months 1–6 and 2.2 (1.1) injections in months 7–12. PT eyes received 4.5 (1.0) injections in months 1–6 and 3.0 (1.2) in months 7–12. In TN eyes, mean (SD) VA increased from 56.4 (16.3) Early Treatment Diabetic Retinopathy Study letters at baseline to 60.1 (19.4) at 12 months (mean [SD] change 3.6 [14.7] letters). PT eyes had stable VA. IOI and PIE rates were consistent with faricimab phase 3 trials. Conclusions These 1-year data support real-world faricimab effectiveness, durability, and safety in nAMD.

Item Type:	Article
Date Type:	Published Online
Status:	In Press
Schools:	Schools > Optometry and Vision Sciences
Publisher:	Springer Science and Business Media LLC
ISSN:	0950-222X
Date of First Compliant Deposit:	16 March 2026
Date of Acceptance:	19 December 2025
Last Modified:	16 Mar 2026 10:31
URI:	https://orca.cardiff.ac.uk/id/eprint/185753

Actions (repository staff only)

Edit Item